Aerosol antibiotics: considerations in pharmacological and clinical evaluation

Current Opinion in Biotechnology

Volumn 19, Issue 6, 2008, Pages 637-643

  Dudley, Michael N ^a   Loutit, Jeff ^a   Griffith, David C ^a  

^a Mpex Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AEROSOLS; ANTIBIOTICS; ATMOSPHERIC AEROSOLS; BACTERIA; BACTERIOLOGY;

ANTIBIOTIC RESISTANCES; ANTIMICROBIAL AGENTS; CHRONIC INFECTIONS; CHRONIC OBSTRUCTIVE PULMONARY DISEASES; CLINICAL EVALUATIONS; CLINICAL TRIALS; CYSTIC FIBROSES; HIGH CONCENTRATIONS; NEW APPROACHES; NEW CLASSES; PSEUDOMONAS AERUGINOSA; PULMONARY INFECTIONS; RECENT PROGRESSES; RESISTANT STRAINS; TARGET SITES; TOBRAMYCIN;

DRUG THERAPY;

AMIKACIN; ANTIBIOTIC AGENT; ARIKACE; CIPROFLOXACIN; COLISTIN; DORIPENEM; LEVOFLOXACIN; MP 376; PLACEBO; TOBRAMYCIN; UNCLASSIFIED DRUG;

AEROSOL; ANTIBIOTIC THERAPY; BACTERIAL COUNT; BACTERIAL PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; HUMAN; INFECTION; LOADING DRUG DOSE; LUNG FUNCTION; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; THROAT IRRITATION;

AEROSOLS; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; CYSTIC FIBROSIS; HUMANS; PSEUDOMONAS INFECTIONS; SPUTUM; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; PSEUDOMONAS AERUGINOSA;

EID: 57049128691     PISSN: 09581669     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.copbio.2008.11.002     Document Type: Review

References (35)

1. Talbot G.H., Bradley J., Edwards Jr. J.E., Gilbert D., Scheld M., Bartlett J.G., et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task of the Infectious Diseases Society of America. Clin Infect Dis 42 (2006) 657-658
2. Gibson R.L., Burns J.L., and Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168 (2003) 918-951. This is a very comprehensive review of the pulmonary complications of CF and rationale for management.
3. Talbot G.H., Bradley J., Edwards Jr. J.E., Gilbert D., Scheld M., and Bartlett J.G. Antimicrobial Availability Task Force of the Infectious Disease Society of America: Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task for of the Infectious Diseases Society of America. Clin Infect Dis 42 (2006) 657-658
4. Sibley C.D., Parkins M.D., Rabin H.R., Duan K., Norgaard J.C., and Surette M.G. A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc Natl Acad Sci U S A 105 (2008) 15070-15075. Interesting paper describing the possible role of chronic pulmonary infection with fastidious S. milleri group streptococci in exacerbations in CF. These organisms are difficult to culture under normal laboratory conditions and thus have not been previously recognized. While additional confirmatory studies are needed, the presence of this organism may necessitate the use of broader spectrum antimicrobials in the management of these patients.
5. Moskowitz S.M., Silva S.J., Mayer-Hamblett N., Pasta D.J., Mink D.R., Mabie J.A., Konstan M.W., and Wegener J.S. For the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis (ESCF): Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatric Pulmonology 43 (2008) 874-881
6. Flume P.A., O'Sullivan B.P., Robinson K.A., Goss C.H., Mogayzel Jr. P.J., Willey-Courand D.B., Bujan J., Finder J., Lester M., Quittell L., et al. Cystic fibrosis pulmonary guidelines, chronic medications for maintenance of lung health. Am J Respir Crit Care Med 176 (2007) 957-969. An excellent evidence-based compendium of recommendations for the management of pulmonary complications in CF from the Cystic Fibrosis Foundation.
7. Craig W.A. Pharmacokinetic-pharmacodynamic parameters: rationale for the antibacterial dosing in mice and men. Clin Infect Dis 26 (1998) 1-12
8. Ambrose P.G., Bhavnani S.M., Rubino C.M., Louie A., Gumbo T., Forrest A., and Drusano G.L. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: its not just for mice anymore. Clin Infect Dis 44 (2007) 79-86. Review of recent use of PK-PD principles in drug development showing the importance of preclinical studies in predicting outcomes in patients in clinical studies. Incorporation of PK-PD principles and studies are now the cornerstone of successful clinical anti-infective drug development programs.
9. Geller D.E., Pitlick W.H., Nardella P.A., Tracewell W.G., and Ramsey B.W. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 122 (2002) 219-226
10. Cooney G.F., Lum B.L., Tomaselli M., and Fiel S.B. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis. J Clin Pharm 34 (1994) 255-259
11. Ramsey B.W., Pepe M.S., Quan J.M., Otto K.L., Montgomery A.B., Williams-Warren J., Vasukhev-K M., Borowitz D., Bowman C.M., Marshall B.C., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis Cystic Fibrosis Inhaled Tobramycin Study Group. New Engl J Med 340 (1999) 23-30. This is the landmark pivotal study showing the efficacy of intermittent inhaled regimens of tobramycin in CF patients.
12. Hunt B.E., Weber A., Berger A., Ramsey B., and Smith A. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob Agents Chemother 39 (1995) 34-39
13. Gibson R.L., Retsch-Bogart G.Z., Oermann C., Milla C., Pilewski J., Daines C., Ahrens R., Leon K., Cohen M., McNamara S., et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 41 (2006) 656-665
14. King P., Lomovskaya O., Griffith D.C., Citron D., Burns J., and Dudley M.N. Bactericidal activity of levofloxacin (MP-376) under varying conditions relevant to chronic pulmonary infections in CF patients. Presented at the North American Cystic Fibrosis Conference (October 2008) (#358)
15. Kuhn R.J. Pharmaceutical considerations in aerosol drug delivery. Pharmacotherapy 22 3 Pt 2 (2002) 80S-85S
16. Geller D.E. The science of aerosol delivery in cystic fibrosis. Pediatr Pulmonol 43 (2008) S5-S17
17. Geller D.E., Konstan M.W., Smith J., Noonberg S.B., and Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 42 (2007) 307-313
18. Merlo C.A., Boyle M.P., Diener-West M., Marshall B.C., Goss C.H., and Lechtzin N. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest 132 (2007) 562-568
19. Boucher R.C. New concepts in the pathogenesis of cystic fibrosis. Eur Respir J 23 (2004) 146-158. This paper summarizes important research showing the role of the depletion of the pericellular fluid at the lung epithelial surface that results in defective mucociliary clearance in CF. This group has also shown that thickened mucous secretions that accumulate in the lungs of CF patients result in areas of low oxygen concentrations; low oxygen concentrations result in reduced potency/activity of aminoglycosides and beta-lactams/monobactams, but less so for fluoroquinolone agents. These differences may have important therapeutic implications.
20. Yassien M., Khardori N., Ahmedy A., and Toama M. Modulation of biofilms of Pseudomonas aeruginosa by quinolones. Antimicrob Agents Chemother 39 (1995) 2262-2268
21. Moskowitz S.M., Foster J.M., Emerson J., and Burns J.L. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 42 (2004) 1915-1922
22. McCoy K.S., Quittner A.L., Oermann C.M., Gibson R.L., Retsch-Bogart G., and Montgomery A.B. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med (2008) (Epub ahead of print; PMID: 18658109)
23. Moss R. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 121 (2002) 55-63
24. Weiner J.R., Toy E.L., Sacco P., and Duh M.S. Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature. Expert Opin Pharmacother 9 (2008) 751-766. Patient-reported outcomes have been identified by regulatory agencies (e.g. FDA) as an important measure of drug efficacy, including the management of pulmonary infections. This review covers several important advances in the development of PROs in CF.
25. Quittner A.L., Buu A., Messer M.A., Modi A.C., and Watrous M. Development and validation of the cystic fibrosis questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 128 (2005) 2347-2354
26. Retsch-Bogart G., Quittner A., Montgomery A.B., Gibson R., McCoy K., Oermann C., and Cooper P. Phase 3 trial measuring improvement in respiratory symptoms in patients with cystic fibrosis following treatment with aztreonam lysine for inhalation. Presented at the 21st North American Cystic Fibrosis Conference, Anaheim, CA. October 3-5, 2007 (2007)
27. Kuhn R.J. Formulation of aerosolized therapeutics. Chest 120 (2001) 94S-98S
28. Hoffmann I.M., Rubin B.K., Iskandar S.S., Schechter M.S., Nagaraj S.K., and Bitzan M.M. Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr Pulmonol 34 (2002) 375-377
29. Edson R.S., Brey R.H., McDonald T.J., Terrell C.L., McCarthy J.T., and Thibert J.M. Vestibular toxicity due to inhaled tobramycin in a patient with renal insufficiency. Mayo Clin Proc 79 (2004) 1185-1191
30. Patakanian L. Inhaled tobramycin-associated hearing loss in an adolescent with renal failure. Pediatr Infect Dis J 25 (2006) 276-278
31. US FDA Public Health Advisory (2007) Colistamethate. http://www.fda.gov/cder/drug/advisory/colistimethate.htm, Posted 6/28/07; accessed 10-19-08.
32. Ortho-McNeil Pharmaceuticals: Doribax prescribing information, 2008.
33. Dhand R., and Sohal H. Pulmonary drug delivery system for inhalation therapy in mechanically ventilated patients. Expert Rev Med Devices 5 (2008) 9-18
34. Niederman M.S., Chastre J., Corkery K., Marcantonio A., Fink K.B., Luyt C.E., Sanchez M., and the Amikacin Study Group. NKTR-061 (inhaled amikacin) reduces intravenous antibiotic use in intubated mechanically ventilated patients during treatment of Gram-negative pneumonia. Presented at the American Thoracic Society (ATS) Meeting, May 18-23 (2007)
35. Niederman M.S., Sanchez M., Corkery K., Guntupalli K., Luyt C.E., and Chastre J. NKTR-061 (inhaled amikacin)achieves high tracheal aspirate concentrations in Gram-negative pneumonia: a pharmacokinetic study. Presented at the American Thoracic Society (ATS) Meeting, May 18-23 (2007)